The Week in Review - 13 February 2016 Save

The Week in Review - 13 Feb 2016 covers:

1.    Acute sacrolilitis diagnosis by CT or bone scan; causes pyogenic, Brucella, crystals, neoplasia
2.    FDA Advisory Vote on Biosimilar
3.    Bisphosphonates are not associated with gastric or esophageal cancer
4.    Psoriatic arthritis risk of SIE and only 6% added risk when using a TNF inhibitor
5.    RWCS – Trajectory of improvement predicts remission success
6.    Dr. Joel Kremer's blog on the History of Methotrexate
7.    FDA Arthritis Advisory Hearing voted 21-3 in favor of approving CT-P13 as a biosimilar of its reference product Remicade – may lead to approval for RA, Psoriasis, Psoriatic arthritis, adult and pediatric Crohn
8.    2016 RWCS Proceedings – Highlights from Drs. Cush, Kavanaugh, Gladman, Bergman, Troum

• SURPRISE Study: add on vs single therapy with Tocilizumab
• Polyarticular JIA – not a good idea to withdraw therapy
• Very Early RA responds best in the AVERT study – Abatacept + MTX.
• Psoriasis review by Dr. Gladman
• Debate on Medical Marijuana
• OA IA steroid injections are not effective 
• Stricter warnings for NSAIDs and CV risk
• Lesinurad is FDA approved as cotherapy for gout
• Gout co-associations